Mainz Biomed N.V. (BST: 4TO)
Germany
· Delayed Price · Currency is EUR
6.64
-0.10 (-1.48%)
At close: Dec 5, 2024
Mainz Biomed Revenue
Mainz Biomed had revenue of $260.39K USD in the quarter ending June 30, 2024, with 4.60% growth. This brings the company's revenue in the last twelve months to $917.20K, up 16.23% year-over-year. In the year 2023, Mainz Biomed had annual revenue of $895.48K with 69.00% growth.
Revenue (ttm)
$917.20K
Revenue Growth
+16.23%
P/S Ratio
n/a
Revenue / Employee
$12.92K
Employees
71
Market Cap
4.10M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 895.48K | 365.60K | 69.00% |
Dec 31, 2022 | 529.88K | -47.47K | -8.22% |
Dec 31, 2021 | 577.35K | 83.78K | 16.98% |
Dec 31, 2020 | 493.57K | 212.17K | 75.40% |
Dec 31, 2019 | 281.39K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMainz Biomed News
- 2 days ago - Quest Diagnostics deal sends Mainz higher - Seeking Alpha
- 2 days ago - Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - GlobeNewsWire
- 2 days ago - EQS-News: Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - Wallstreet:Online
- 5 days ago - Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering - GlobeNewsWire
- 8 days ago - Mainz Biomed prices $8M offering of shares and warrants - Seeking Alpha
- 9 days ago - Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules - GlobeNewsWire
- 18 days ago - Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific - Benzinga
- 18 days ago - Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific - Benzinga